Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 1/2012

Open Access 01-01-2012 | Original Article

Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet

Authors: M. R. McClung, P. D. Miller, J. P. Brown, J. Zanchetta, M. A. Bolognese, C. L. Benhamou, A. Balske, D. E. Burgio, J. Sarley, L. K. McCullough, R. R. Recker

Published in: Osteoporosis International | Issue 1/2012

Login to get access

Abstract

Summary

Dosing regimens of oral bisphosphonates are inconvenient and contribute to poor compliance. The bone mineral density response to a once weekly delayed-release formulation of risedronate given before or following breakfast was non-inferior to traditional immediate-release risedronate given daily before breakfast. Delayed-release risedronate is a convenient regimen for oral bisphosphonate therapy.

Introduction

We report the results of a randomized, controlled, clinical study assessing the efficacy and safety of a delayed-release (DR) 35 mg weekly oral formulation of risedronate that allows patients to take their weekly risedronate dose before or immediately after breakfast.

Methods

Women with postmenopausal osteoporosis were randomly assigned to receive risedronate 5 mg immediate-release (IR) daily (n = 307) at least 30 min before breakfast, or risedronate 35 mg DR weekly, either at least 30 min before breakfast (BB, n = 308) or immediately following breakfast (FB, n = 307). Bone mineral density (BMD), bone turnover markers (BTMs), fractures, and adverse events were evaluated. The primary efficacy variable was percent change from baseline in lumbar spine BMD at Endpoint.

Results

Two hundred fifty-seven subjects (83.7%) in the IR daily group, 252 subjects (82.1%) in the DR FB weekly group, and 258 subjects (83.8%) in the DR BB weekly group completed 1 year. Both DR weekly groups were determined to be non-inferior to the IR daily regimen. Mean percent changes in hip BMD were similar across groups. The magnitude of BTM response was similar across groups; some statistical differences were seen that were small and deemed by investigators to have no major clinical importance. The incidence of adverse events leading to withdrawal and serious adverse events were similar across treatment groups. All three regimens were well tolerated.

Conclusions

Risedronate 35 mg DR weekly is similar in efficacy and safety to risedronate 5 mg IR daily, and will allow patients to take their weekly risedronate dose immediately after breakfast.
Literature
1.
2.
3.
4.
Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm 4(5):488–492
5.
Fleisch H (2000) Pharmacokinetics. In: Bisphosphonates in bone disease: from the laboratory to the patient. 4th ed. San Diego: Academic. p. 56–62
6.
Barrett J, Worth E, Bauss F, Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951–965PubMedCrossRef
7.
Ogura Y, Gohsho A, Cyong J-C, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J Bone Miner Metab 22(2):120–126PubMedCrossRef
8.
Agrawal S, Krueger DC, Engelke JA et al (2006) Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 54(5):790–795PubMedCrossRef
9.
Kendler DL, Ringe JD, Ste-Marie LG et al (2009) Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 20(11):1895–1902PubMedCrossRef
10.
Genant HK, Wu CY, Van Kuik C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137–1148PubMedCrossRef
11.
Brown JP, Kendler DL, McClung MR et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71(2):103–111PubMedCrossRef
12.
Reginster JY, Minne HW, Sorensen O et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83–91PubMedCrossRef
13.
Delmas PD, McClung MR, Zanchetta JR et al (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42(1):36–42PubMedCrossRef
14.
15.
Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344–1352PubMedCrossRef
16.
McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333–340PubMedCrossRef
17.
Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20(8):1315–1322PubMedCrossRef
18.
Delmas PD, Silvano A, Strugala C et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one year results from the dosing intravenous administration study. Arthritis Rheum 54(6):1838–1846PubMedCrossRef
19.
McClung MR, Benhamou C-L, Man Z et al (2007) The efficacy and tolerability of a monthly dosing regimen of 75 mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis-1 year study results [abstract]. Osteoporos Int 18(Suppl 2):S217–S218
Metadata
Title
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet
Authors
M. R. McClung
P. D. Miller
J. P. Brown
J. Zanchetta
M. A. Bolognese
C. L. Benhamou
A. Balske
D. E. Burgio
J. Sarley
L. K. McCullough
R. R. Recker
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Osteoporosis International / Issue 1/2012
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-011-1791-y

Other articles of this Issue 1/2012

Osteoporosis International 1/2012 Go to the issue

Original Article

Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys

Original Article

Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials

Original Article

Physical activity, calcium intake and childhood bone mineral: a population-based cross-sectional study

Original Article

Excess body fat is associated with higher risk of vertebral deformities in older women but not in men: a cross-sectional study

Erratum

Erratum to: Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis

Letter to the Editor

Validation of cross-sectional studies with long-term longitudinal studies